The firm banked €187 million in net profit in Q3, compared with €181 million it registered in the same period in 2024.
In the second quarter (Q2) of this year, Philips had posted profits of €240 million.
“In this quarter we maintained our momentum,” chief executive Roy Jakobs said in a statement.
Traders welcomed the results, pushing the stock sharply higher at the opening bell.
Philips shares were up more than 1% in the early minutes of trading, a top gainer in an overall market that was down more than 1%.
The company also maintained its forecast for an increase in annual sales of between 1% and 3%.
In Q3, sales came in at €4.3 billion, the same as during Q2 quarter.
Orders were up 8%, driven by what the firm said was “sustained double-digit growth” in the US.
Philips continues to battle legal difficulties over a 2021 recall of DreamStation machines for sleep apnoea, a disorder in which breathing intermittently stops during sleep.
It recalled millions of machines over concerns users were at risk of inhaling or swallowing pieces of toxic sound-absorbing foam and fears it could potentially cause cancer.
The firm agreed in 2024 to pay US$1.1 billion to settle US lawsuits related to the recall, although it did not acknowledge liability.
In September, sources close to the case told AFP that a magistrate in France was looking into whether Philips committed aggravated fraud in relation to the machines.
The Paris prosecutor’s office confirmed to AFP that it had received 104 complaints from individuals, two from associations, as well as an alert from France’s medical device regulator.
Philips said that probe, opened in June, concerned its actions during the 2021 recall and had no bearing on the quality of its current machines.
In July, Philips said it expected a hit of between €150 million and €200 million this year from US tariffs.
It had earlier estimated that impact as high at €300 million and the change in forecast sent its shares more than 10% higher in July.
Long known for its light bulbs and television sets, the Dutch consumer giant has since refocused its production on medical equipment.